Suppr超能文献

吡格列酮增强肝硬化大鼠胃溃疡的抗溃疡作用:一氧化氮和白细胞介素-1β的作用。

Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1β.

机构信息

Department of Pharmacology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

出版信息

Pharmacol Rep. 2013;65(1):134-43. doi: 10.1016/s1734-1140(13)70971-x.

Abstract

BACKGROUND

The frequency of gastrointestinal ulcerations is higher in cirrhotic patients than in the normal population. It has been shown that pioglitazone exhibits gastroprotective actions. This study was designed to investigate the effect of pioglitazone, on the gastric mucosal lesions in cirrhotic rats.

METHODS

Different groups of bile duct-ligated and sham animals received solvent, or 5, 10 or 15 mg/kg pioglitazone, for 5 days in the last days of 28-day period of cirrhosis. On day 28, rats were killed 1 h after oral ethanol administration and the area of gastric lesions was measured. The serum of rats was also collected to evaluate serum concentrations of TNF-α and IL-1β. Histopathologic examination of liver specimens was also done with hematoxylin-eosin to show possible toxicity of pioglitazone in cirrhosis.

RESULTS

Pretreatment with pioglitazone dose dependently attenuated gastric lesions induced by ethanol in both sham and cirrhotic rats, but this effect was more prominent in cirrhotic ones. L-NAME, a non-selective inhibitor of nitric oxide synthase, decreased pioglitazone-induced gastric healing effect in cirrhotic rats, while aminoguanidine, a selective inducible nitric oxide synthase inhibitor, increased pioglitazone-induced gastric healing effect in the same group. The protective effect of pioglitazone was accompanied by a fall in serum IL-1β level.

CONCLUSIONS

Chronic treatment with pioglitazone exerts a more prominent gastroprotective effect on the stomach ulcers of cirrhotic rats compared to control group probably due to constitutive nitric oxide synthase induction or inducible nitric oxide synthase inhibition. Suppression of IL-1β could be another mechanism in pioglitazone-induced healing effect of gastric ulcers in cirrhotic rats.

摘要

背景

肝硬化患者的胃肠道溃疡发生率高于普通人群。已证实吡格列酮具有胃保护作用。本研究旨在探讨吡格列酮对肝硬化大鼠胃黏膜病变的影响。

方法

胆管结扎和假手术的不同组动物在 28 天肝硬化周期的最后几天接受溶剂或 5、10 或 15mg/kg 吡格列酮治疗 5 天。在第 28 天,大鼠在口服乙醇后 1 小时处死,并测量胃损伤面积。还收集大鼠血清以评估 TNF-α和 IL-1β的血清浓度。用苏木精-伊红对肝组织标本进行组织病理学检查,以显示吡格列酮在肝硬化中的潜在毒性。

结果

吡格列酮预处理剂量依赖性地减轻了乙醇诱导的假手术和肝硬化大鼠的胃损伤,但在肝硬化大鼠中效果更为明显。非选择性一氧化氮合酶抑制剂 L-NAME 降低了肝硬化大鼠中吡格列酮诱导的胃愈合作用,而选择性诱导型一氧化氮合酶抑制剂氨基胍增加了同一组中吡格列酮诱导的胃愈合作用。吡格列酮的保护作用伴随着血清 IL-1β水平的下降。

结论

与对照组相比,慢性吡格列酮治疗对肝硬化大鼠的胃溃疡具有更显著的胃保护作用,这可能归因于组成型一氧化氮合酶诱导或诱导型一氧化氮合酶抑制。抑制 IL-1β可能是吡格列酮诱导肝硬化大鼠胃溃疡愈合作用的另一种机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验